Royal Australian Navy - 👉 Bachelor of Electronic and Communications Engineering
Releaf, Business Of Cannabis, CPD, Cannabis Now Magazine, High Times, Cookies Seeds, Fast Buds, MSNL, Paradise Seeds, Premium Cultivars
Sam North is a content writer at Releaf, specialising in medical cannabis, digital health, and patient education within a UK regulatory framework. After a decade immersed in the cultivation side of the cannabis industry, Sam moved into digital in 2020. He worked across the recreational space with seed companies, CBD brands, and cannabis publications, before transitioning into the medical cannabis sector in early 2023 and joining Releaf in April of that year. Today, his work spans both content and SEO, with a focus on how the two support patient understanding and long-term organic growth. He writes and shapes educational content, research breakdowns, and patient-facing web copy, ensuring it is clear, clinically accurate, and aligned with UK compliance requirements. At Releaf, Sam’s focus is on making medical cannabis more understandable and accessible to patients, while maintaining a high standard of accuracy, compliance, and trust.
New national guidance instructs UK police officers to treat people with a legal UK medical cannabis prescription as “patients first, suspects second”. This guide explains what officers may check, what patients are not required to carry, how Cancard is viewed, and how the Releaf medical cannabis card fits in, with clear, practical advice for patients.
Choosing between Releaf+ and Pay As You Go is about how you want to manage costs and ongoing care. Both options provide access to Releaf’s specialist doctors and prescribed medical cannabis. This guide explains how each option works in practice, including pricing, follow-ups, repeat prescriptions, and what to expect as your treatment continues.
Releaf Protect offers legal guidance for medical cannabis patients through a dedicated helpline for eligible Releaf+ members. It is designed to help you understand how UK law applies to your prescription and what reasonable next steps may look like if your medication is questioned at work, in public, or by authorities.
Lower back pain is one of the most common reasons people seek medical support. This guide explains the entire gamut of lower back pain, what causes it, and the treatment options that may help, including medical cannabis, physiotherapy, exercises, and when to seek further care.
Over the past year, more than 50 patients chose to share their stories with Releaf. Taken together, those experiences shaped how we listened, learned, and supported people throughout 2025. This reflection brings together five patient voices that echo many of the challenges and moments we heard across the year, and how those voices continue to shape the way we care, communicate, and build support around our patients.
Releaf has introduced a dedicated veteran discount to help UK Armed Forces veterans access legal medical cannabis treatment. The discount includes a cost-free Initial Consultation with a specialist clinician and three months of Releaf+ membership, supporting veterans with personalised, clinician-led care and ongoing support during the early stages of treatment.
With the holiday season less than two weeks away, we want to make sure each and every Releaf patient is well-prepared for the slight changes to our normal operating schedule, along with the minor adjustments to medication delivery during this year's festive period.
Reports suggest that fewer than 1% of eligible UK specialists are trained to prescribe medical cannabis. This gap leaves many patients without informed support. This outline explains why the gap exists and how Releaf’s clinicians follow a structured, evidence-based training pathway that leads the industry. It also highlights Releaf’s wider educational work, including police workshops that improve understanding of legal patient access.
Sleep apnoea can affect concentration, energy levels and overall wellbeing. This updated guide explains how medical cannabis and CBD may support people living with sleep apnoea, what current research shows and how treatment works in the UK. It also covers risks, product types and the role of established treatments such as CPAP.
A recent scoping review has dug into how cannabinoids interact with inflammation, joint tissue, and pain signalling in rheumatoid arthritis. This article breaks down what the researchers found, how THC and CBD influence key inflammatory pathways, and what these insights may mean for people living with arthritis in the UK. We also look at how this evidence compares with current patient experiences.
This year, our patient survey, the largest of its kind in the UK, found that 97% of patients reported an improved quality of life and 91% they were likely to recommend medical cannabis to others who may be eiligible.
This Men’s Health Month, Releaf's study of active UK medical cannabis patients (the largest to date) shows how men are using treatment to improve their quality of life, reduce chronic pain, support their mental and general wellbeing, and move beyond outdated stigma. The data reflects a wider shift toward openness, ownership, and long-term health management among men seeking more stable and effective support.
Releaf has officially launched in Germany, marking its first international expansion and a major milestone in its mission to build Europe’s most trusted cannabis access platform. The move signals a bold step towards improving access to safe, evidence-based medical cannabis treatment across the continent.
Available right now, Releaf’s new Starter Kits give patients the choice between the compact PAX Mini and the medical-grade Storz & Bickel Venty. Each kit includes carefully selected accessories and CBD products designed to support precise, effective administration of prescribed medical cannabis. Available exclusively through the Releaf Shop for anyone with a Releaf login.
CBG is attracting attention as one of the most versatile minor cannabinoids in medical cannabis. This blog brings together reflections from Releaf’s UK medical cannabis specialists on what early research and clinical experience suggest about its potential in patient care.
To mark the seventh anniversary of medical cannabis legalisation in the UK, Releaf conducted a nationwide study involving 1,669 patients - the largest survey of prescribed medical cannabis patients ever undertaken in the country.
Research into cannabinoids for skin cancer is accelerating. Studies from 2024 and 2025 suggest that CBD (and THC) may influence inflammation, oxidative stress, and cell growth, but clinical evidence in humans is still limited. This article explains the science, safety, and how UK patients can access medical cannabis treatment
CBD is being actively studied for its effects on skin health, from inflammation and acne to itch relief, infections, hydration, and anti-ageing. This guide reviews the newest 2025 research, practical benefits, and potential risks, so you can make an informed choice about whether CBD may support your skin.
To mark World Mental Health Day 2025, we continue our Decoding Cannabis blog series by exploring a major 2024 review of 156 studies on medical cannabis and depression. The evidence suggests that balanced THC and CBD prescriptions may help support mood and emotional well-being, while THC-heavy options can sometimes worsen symptoms. The findings highlight cannabis’s emerging role in UK mental health care
The UK government has launched a new review into medical cannabis laws, asking patients, families, and healthcare professionals to share their experiences. With Releaf patients already contributing to research efforts with our survey results due for release in November, this marks a crucial step in shaping access to cannabis-based medicines.
The first randomised controlled trial of cannabis for migraine compared THC, CBD, THC with CBD, and placebo. Results showed that THC and CBD combined offered the strongest benefits, while THC alone provided partial relief and CBD alone had a limited effect. We explain the findings, what they mean for patients, safety considerations, and how this all affects medical cannabis access in the UK.
When people look up cannabis strains, they often find a jumble of terms. In medical care, it’s a bit more focused. Here’s what patients in the UK can expect: THC-dominant, CBD-dominant, and balanced strains, plus terpene profiles that shape effects. Here, Releaf makes patient access simple and reliable.
Recent research suggests that THC-dominant cannabis oil affects core Alzheimer’s symptoms like agitation, appetite loss, cognitive function and sleep. We decode the study and explain what it means for families navigating dementia care in the UK.
Medical cannabis is reshaping both health and economics in the UK. From easing NHS costs and creating new jobs, to helping patients return to work and family life, the benefits extend far beyond the clinic. This article explores the ripple effects that show medical cannabis is part of a wider economic and social story.
"Since starting my treatment plan with Releaf, I’m genuinely shocked at how well it has worked."Chloe Durrington, Releaf patient
